By Fineline Cube 
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics, Inc. has secured exclusive worldwide rights to develop and commercialize VVD-214 (RO7589831), a clinical-stage covalent Werner helicase (WRN) inhibitor. This move significantly enhances Bayer’s oncology pipeline.
Drug Development Background
VVD-214 was originally discovered and developed under a 2020 exclusive global collaboration and licensing agreement between Vividion and Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY). Vividion utilized its innovative discovery platform to target the traditionally “undruggable” WRN helicase for precision cancer therapeutics.
Clinical Data and Future Plans
Preliminary Phase I data presented at the 2025 AACR Annual Meeting showed that VVD-214 demonstrates favorable tolerability and promising antitumor activity. Vividion will continue to advance the clinical development of the drug.-Fineline Info & Tech